**EQUITY RESEARCH - RESULTS FLASH** 







# **BDMS TB**

**TARGET PRICE** 

**UP/DOWNSIDE** 

**TP vs CONSENSUS** 

**CLOSE** 



THB36.50

THB25.75

+41.7%

+3.8%

# THAILAND / HEALTH CARE SERVICES

# 3Q24 results at first glance

3Q24 core profit grew by 9% y-y and hit a record high of THB4.2b, in line with our estimate

BANGKOK DUSIT MEDICAL SERVICES

### Highlights


- BDMS reported a core profit of THB4.2b in 3Q24 (+9% y-y, +27% qq), in line with our estimate.
- Hospital revenue grew 6% y-y. International patient revenue grew 8% y-y, driven by patient revenue from Qatar (+47% y-y), China (+32% y-y) and the UAE (+29% y-y). Meanwhile, Thai patient revenue grew 6% y-y.
- COGS increased by 7% y-y and SG&A increased by 4% y-y. As a result, the 3Q24 EBITDA margin slightly improved to 25.0% (vs 24.7% in 3Q23).
- 9M24 core profit grew by 12% y-y to THB11.7b and accounted for 73% of our 2024 core profit forecast of THB16.0b.

#### **Outlook**

- We believe the revenue growth momentum will continue in 4Q24, driven by international patients, leading 2024 revenue to nearly hit management's guidance of 10% growth.
- BDMS is trading at an attractive valuation of 23x 2025E P/E, lower than its five-year average of 31x.

# **KEY STOCK DATA**

YE Dec (THB m)	2023	2024E	2025E	2026E
Revenue	102,110	111,730	120,675	130,342
Net profit	14,375	15,971	17,640	19,341
EPS (THB)	0.90	1.00	1.11	1.22
vs Consensus (%)	-	0.3	2.1	1.1
EBITDA	24,740	27,071	29,721	32,363
Recurring net profit	14,375	15,971	17,640	19,341
Core EPS (THB)	0.90	1.00	1.11	1.22
EPS growth (%)	14.0	11.1	10.4	9.6
Core P/E (x)	28.5	25.6	23.2	21.2
Dividend yield (%)	2.5	2.7	2.7	3.0
EV/EBITDA (x)	17.0	15.5	14.0	12.7
Price/book (x)	4.3	4.1	3.8	3.6
Net debt/Equity (%)	8.8	6.7	1.6	(3.3)
ROE (%)	15.5	16.4	17.1	17.6



Share price performance	1 Month	3 Month	12 Month
Absolute (%)	(10.4)	(7.2)	(3.7)
Relative to country (%)	(8.9)	(16.7)	(7.4)
Mkt cap (USD m)			11,757
3m avg. daily turnover (USD m)			46.4
Free float (%)			70
Major shareholder		Thai N\	/DR (12%)
12m high/low (THB)		3	1.25/25.00
Issued shares (m)			15,892.00

Sources: Bloomberg consensus; FSSIA estimates



Teerapol Udomvej, CFA Fundamental Investment Analyst on Securities; License no. 080523 teerapol.udo@fssia.com, +66 2646 9969

Exhibit 1: BDMS - 3Q24 results summary

	3Q23	4Q23	1Q24	2Q24	3Q24	Cha	nge	2023	2024E	Chang
	(THB m)	(q-q %)	(y-y %)	(THB m)	(THB m)	(y-y %				
Sales	26,699	26,726	26,930	26,058	28,536	10	7	102,110	111,730	
- Hospital revenue	25,473	25,379	25,526	24,694	27,108	10	6	97,077	106,294	
- Other revenue	1,227	1,346	1,404	1,364	1,428	5	16	5,034	5,436	
COGS (incl depreciation)	(16,469)	(16,389)	(16,736)	(16,664)	(17,634)	6	7	(63,412)	(69,248)	
Gross profit	10,230	10,337	10,194	9,394	10,901	16	7	38,698	42,482	1
SG&A	(5,106)	(5,191)	(4,893)	(5,146)	(5,313)	3	4	(19,806)	(21,560)	
Operating profit <sup>1)</sup>	5,124	5,146	5,301	4,248	5,588	32	9	18,892	20,922	1
Net other income	7	19	9	23	20	(15)	198	43	48	•
Interest income	48	52	48	47	40	(15)	(17)	173	110	(3
Interest expense	(122)	(126)	(113)	(111)	(102)	(7)	(16)	(547)	(501)	
Pretax profit	5,057	5,091	5,246	4,208	5,546	32	10	18,563	20,579	·
ncome Tax	(1,025)	(1,038)	(1,042)	(756)	(1,153)	53	13	(3,755)	(4,116)	
Associates	21	22	13	14	24	70	15	89	98	
Minority interest	(163)	(123)	(143)	(131)	(171)	30	5	(522)	(590)	1
Core profit	3,890	3,952	4,074	3,335	4,246	27	9	14,375	15,971	1
Extraordinaries, GW & FX	-,	-,	.,	-,	-,			0	0	
Reported net profit	3,890	3,952	4,074	3,335	4,246	27	9	14,375	15,971	1
noponou not prom	3,333	0,002	.,	5,555	.,			,		
Outstanding shares (m)	15,892	15,892	15,892	15,892	15,892	0	0	15,892	15,892	
Core EPS (THB)	0.24	0.25	0.26	0.21	0.27	27	9	0.90	1.00	
EPS (THB)	0.24	0.25	0.26	0.21	0.27	27	9	0.90	1.00	
COGS Excl depreciation	14,999	14,886	15,259	15,161	16,087	6	7	57,564	63,099	
Depreciation	1,470	1,503	1,477	1,503	1,548	3	5	5,848	6,149	
EBITDA <sup>2)</sup>	6,594	6,649	6,778	5,751	7,136	24	8	24,740	27,071	
ey ratios	(%)	(%)	(%)	(%)	(%)	(ppt)	(ppt)	(%)	(%)	(p
Gross margin	38	39	38	36	38	2	(0)	38	38	
G&A/Revenue	19	19	18	20	19	(1)	(1)	19	19	(
BITDA margin	25	25	25	22	25	3	0	24	24	
let profit margin	15	15	15	13	15	2	0	14	14	
perating stats	(%)	(%)	(%)	(%)	(%)					
OPD revenue growth y-y	14	10	13	12	12					
OPD volume growth y-y	0	5	12	7	-					
OPD revenue per head growth y-y	14	5	1	2	-					
PD revenue growth y-y	9	15	8	5	9					
PD volume growth y-y	20	17	17	(2)	-					
PD revenue per head growth y-y	(9)	(2)	(7)	6	-					
Гhai revenue growth y-y	9	10	10	5	6					
nternational revenue growth y-y	19	18	12	11	8					

<sup>1)</sup> Gross profit calculated by revenue – COGS including depreciation; 2) EBITDA calculated by operating profit + operating income – depreciation Sources: BDMS; FSSIA estimates

# **Financial Statements**

Bangkok Dusit Medical Services

Profit and Loss (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Revenue	92,968	102,110	111,730	120,675	130,342
Cost of goods sold	(58,329)	(63,412)	(69,248)	(74,571)	(80,375)
Gross profit	34,638	38,698	42,482	46,104	49,967
Other operating income	-	-	-	-	-
Operating costs	(17,655)	(19,806)	(21,560)	(23,045)	(24,761)
Operating EBITDA	22,933	24,740	27,071	29,721	32,363
Depreciation	(5,950)	(5,848)	(6,149)	(6,662)	(7,157)
Goodwill amortisation	-	-	-	-	-
Operating EBIT	16,984	18,892	20,922	23,059	25,206
Net financing costs	(552)	(373)	(391)	(364)	(294)
Associates	42	89	98	108	119
Recurring non-operating income	50	133	146	161	177
Non-recurring items	0	0	0	0	0
Profit before tax	16,481	18,652	20,677	22,856	25,088
Tax	(3,227)	(3,755)	(4,116)	(4,550)	(4,994)
Profit after tax	13,254	14,897	16,561	18,307	20,094
Minority interests	(648)	(522)	(590)	(667)	(753)
Preferred dividends	-	-	-	-	-
Other items	-	-	-	-	-
Reported net profit	12,606	14,375	15,971	17,640	19,341
Non-recurring items & goodwill (net)	0	0	0	0	0
Recurring net profit	12,606	14,375	15,971	17,640	19,341
Per share (THB)					
Recurring EPS *	0.79	0.90	1.00	1.11	1.22
Reported EPS	0.79	0.90	1.00	1.11	1.22
DPS	0.50	0.65	0.70	0.70	0.78
Diluted shares (used to calculate per share data)	15,892	15,892	15,892	15,892	15,892
Growth					
Revenue (%)	23.1	9.8	9.4	8.0	8.0
Operating EBITDA (%)	32.2	7.9	9.4	9.8	8.9
Operating EBIT (%)	54.1	11.2	10.7	10.2	9.3
Recurring EPS (%)	63.0	14.0	11.1	10.4	9.6
Reported EPS (%)	58.8	14.0	11.1	10.4	9.6
Operating performance					
Gross margin inc. depreciation (%)	37.3	37.9	38.0	38.2	38.3
Gross margin exc. depreciation (%)	43.7	43.6	43.5	43.7	43.8
Operating EBITDA margin (%)	24.7	24.2	24.2	24.6	24.8
Operating EBIT margin (%)	18.3	18.5	18.7	19.1	19.3
Net margin (%)	13.6	14.1	14.3	14.6	14.8
Effective tax rate (%)	19.6	20.2	20.0	20.0	20.0
Dividend payout on recurring profit (%)	63.0	71.9	69.7	63.4	63.8
Interest cover (X)	30.8	51.0	53.9	63.8	86.2
Inventory days	14.7	14.7	14.7	14.8	14.8
Debtor days	38.5	39.4	37.8	35.0	32.4
Creditor days	39.1	41.5	41.8	42.2	42.2
Operating ROIC (%)	15.8	16.1	17.1	18.3	19.6
ROIC (%)	12.7	13.1	14.0	15.1	16.2
ROE (%)	14.5	15.5	16.4	17.1	17.6
ROA (%)	10.1	10.7	11.5	12.1	12.5
* Pre exceptional, pre-goodwill and fully diluted					
Revenue by Division (THB m)	2022	2023	2024E	2025E	2026E
Thai patient revenue	67,286	70,866	76,151	81,810	87,876
International patient revenue	21,248	26,211	30,142	33,157	36,472

Sources: Bangkok Dusit Medical Services; FSSIA estimates

# **Financial Statements**

Bangkok Dusit Medical Services

Cash Flow (THB m) Year Ending Dec	2022	2023	2024E	2025E	2026E
Recurring net profit	12,606	14,375	15,971	17,640	19,341
Depreciation	5,950	5,848	6,149	6,662	7,157
Associates & minorities	-	-	-	-	-
Other non-cash items	1,275	1,203	590	667	753
Change in working capital	720	161	1,242	1,129	1,229
Cash flow from operations	20,551	21,588	23,953	26,098	28,480
Capex - maintenance Capex - new investment	(14,953)	(11,612)	(11,173)	(9,654)	(10,427)
Net acquisitions & disposals	(386)	(290)	0	0	0
Other investments (net)	(300)	(290)	-	-	-
Cash flow from investing	(15,340)	(11,902)	(11,173)	(9,654)	(10,427)
Dividends paid	(7,943)	(10,343)	(11,124)	(11,180)	(12,348)
Equity finance	0	0	0	0	0
Debt finance	4,764	(5,460)	(500)	(500)	(500)
Other financing cash flows	299	612	0	0	0
Cash flow from financing	(2,880)	(15,190)	(11,624)	(11,680)	(12,848)
Non-recurring cash flows	-	-	-	-	-
Other adjustments	0	0	0	0	0
Net other adjustments	0	0	0	0	0
Movement in cash	2,330	(5,505)	1,155	4,764	5,205
Free cash flow to firm (FCFF)	5,842.84	10,232.29	13,280.45	16,930.40	18,525.27
Free cash flow to equity (FCFE)	10,273.66	4,838.23	12,279.70	15,943.65	17,552.52
Per share (THB)					
FCFF per share	0.37	0.64	0.84	1.07	1.17
FCFE per share	0.65	0.30	0.77	1.00	1.17
Recurring cash flow per share	1.25	1.35	1.43	1.57	1.71
Colones Sheet (TUR m) Veer Ending Dog	2022	2023	2024E	2025E	2026E
Balance Sheet (THB m) Year Ending Dec					
Tangible fixed assets (gross)	155,412	165,315	176,488	186,142	196,569
Less: Accumulated depreciation	(63,503)	(67,642)	(73,791)	(80,453)	(87,609)
Tangible fixed assets (net)	91,909	97,673	102,697	105,689	108,960
ntangible fixed assets (net)	19,160	19,376	19,376	19,376	19,376
Long-term financial assets	-	-	-	-	-
nvest. in associates & subsidiaries	1,986	2,276	2,276	2,276	2,276
Cash & equivalents	14,972	9,467	10,622	15,386	20,591
A/C receivable	10,484	11,558	11,558	11,558	11,558
nventories	2,211	2,420	2,652	2,855	3,078
Other current assets	132	101	110	119	129
Current assets	27,799	23,545	24,943	29,918	35,355
Other assets	689	726	726	726	726
Fotal assets	141,543	143,596	150,017	157,984	166,693
Common equity	89,879	95,242	100,089	106,549	113,542
Vinorities etc. Fotal shareholders' equity	3,834	3,630 <b>98,872</b>	4,220	4,887 <b>111,436</b>	5,641 <b>119,183</b>
	<b>93,713</b> 23,062	18,134	<b>104,309</b> 17,634	•	16,634
_ong term debt Other long-term liabilities				17,134	
Long-term liabilities	10,032	10,973	10,973 <b>28,607</b>	10,973	10,973 <b>27,607</b>
A/C payable	<b>33,094</b> 6,176	<b>29,107</b> 6,901	7,565	<b>28,107</b> 8,141	8,778
Short term debt	532	0,901	0	0,141	0,770
Other current liabilities	8,028	8,715	9,536	10,300	11,125
Current liabilities	14,736	15,616	17,101	18,441	19,903
Fotal liabilities and shareholders' equity	141,543	143,596	150,017	157,984	166,693
Net working capital	(1,377)	(1,538)	(2,780)	(3,909)	(5,138)
nvested capital	112,367	118,513	122,294	124,157	126,199
Includes convertibles and preferred stock which is being			,		.==,
Per share (THB)					
,	5.66	5.00	6.30	6.70	7 1/
Book value per share Fangible book value per share	5.66 4.45	5.99 4.77	6.30 5.08	6.70 5.49	7.14 5.93
Financial strength	4.40	7.11	5.06	5.48	ე.შე
-	0.0	0.0	6.7	4.0	(0.0)
Net debt/equity (%)	9.2	8.8	6.7	1.6	(3.3)
Net debt/total assets (%)	6.1 1.9	6.0 1.5	4.7 1.5	1.1 1.6	(2.4)
Current ratio (x) CF interest cover (x)	1.9 19.6	1.5 14.0	1.5 32.4	1.6 44.8	1.8 60.6
/aluation	2022	2023	2024E	2025E	2026E
	32.5	28.5	25.6	23.2	21.2
Recurring P/E (x) *		40.4	36.3	32.9	30.0
Recurring P/E @ target price (x) *	46.0	<u> </u>		22.2	
Recurring P/E @ target price (x) * Reported P/E (x)	32.5	28.5	25.6	23.2	
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%)	32.5 1.9	2.5	2.7	2.7	3.0
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x)	32.5 1.9 4.6	2.5 4.3	2.7 4.1	2.7 3.8	3.0 3.6
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	32.5 1.9 4.6 5.8	2.5 4.3 5.4	2.7 4.1 5.1	2.7 3.8 4.7	3.0 3.6 4.3
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x) EV/EBITDA (x) **	32.5 1.9 4.6 5.8 18.4	2.5 4.3 5.4 17.0	2.7 4.1 5.1 15.5	2.7 3.8 4.7 14.0	3.6 4.3 12.7
Recurring P/E @ target price (x) * Reported P/E (x) Dividend yield (%) Price/book (x) Price/tangible book (x)	32.5 1.9 4.6 5.8	2.5 4.3 5.4	2.7 4.1 5.1	2.7 3.8 4.7	3.0 3.6

Sources: Bangkok Dusit Medical Services; FSSIA estimates

# **Bangkok Dusit Medical Serv (BDMS TB)**

FSSIA ESG rating

# **Exhibit 2: FSSIA ESG score implication**

74.00 /100

Rating	Score	Implication
****	>79-100	Leading its industry peers in managing the most significant ESG risks which not only better cost efficiency but also lead to higher profitability.
***	>59-79	A mixed track record of managing the most significant ESG risks and opportunities relative to industry peers.
***	>39-59	Relevant ESG materiality matrix has been constructively addressed, well-managed and incorporated into day-to-day operations, in which targets and achievements are evaluated annually.
**	>19-39	Relevant ESG materiality matrix has been identified with key management in charge for progress to be followed up on and to provide intensive disclosure. Most targets are conventional and achievable.
*	1-19	The company has adopted the United Nations Sustainable Development Goals (UN SDGs), established sustainability management guidelines and fully complies with regulations or ESG suggested guidance from related organizations such as the SET and SEC.

Sources: FSSIA estimates

Exhibit 3: ESG – peer comparison

	FSSIA			Domes	stic ratings	;				Glo	bal ratings			Bloomberg	
	ESG score	DJSI	SET THSI	THSI	CG score	AGM level	Thai CAC	Morningstar ESG risk	ESG Book	MSCI	Moody's	Refinitiv	S&P Global	ESG score	Disclosure score
SET100	69.20	5.34	4.40	4.40	4.76	4.65	3.84	Medium	51.76	BBB	20.87	58.72	63.91	3.72	28.17
Coverage	67.12	5.11	4.15	4.17	4.83	4.71	3.53	Medium	52.04	ВВ	16.97	56.85	62.09	3.40	31.94
BCH	39.71				4.00	5.00	Certified	High	48.21			27.19	18.00	3.52	47.60
BDMS	74.00	Υ	Y	Y	5.00	4.00		Medium	61.06	AA	34.00	59.83	72.00	3.45	58.92
ВН	51.21				4.00	4.00		Medium	64.29	Α	29.00	59.03	27.00	5.08	47.79
CHG	38.25				4.00	5.00		High	55.35			59.57	21.00	2.34	50.24
PR9	54.08		Y	Y	5.00	5.00	Certified	High	71.12			62.39		2.43	37.90
PRINC	18.00				4.00	4.00	Certified								
RAM	11.75				3.00			High							
THG	18.75				5.00	5.00		High							
VIBHA	20.88				4.00	3.00	Declared	High					17.00		

Sources: <u>SETTRADE.com</u>; FSSIA's compilation

# Exhibit 4: ESG score by Bloomberg

FY ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 2022
ESG financial materiality scores - ESG score	1.08	1.05	2.21	2.76	3.74	3.77	3.76	3.45
BESG environmental pillar score	0.00	0.00	2.04	4.49	4.17	3.84	3.24	2.25
BESG social pillar score	0.14	0.14	1.24	1.48	3.40	3.53	3.54	3.59
BESG governance pillar score	4.56	4.40	4.37	4.19	4.03	4.13	4.51	4.12
ESG disclosure score	32.33	32.33	46.90	47.34	57.35	57.69	58.34	58.92
Environmental disclosure score	0.00	0.00	22.74	24.07	52.31	52.31	54.27	56.00
Social disclosure score	13.21	13.21	34.22	34.22	36.03	37.06	37.06	37.06
Governance disclosure score	83.59	83.59	83.59	83.59	83.59	83.59	83.59	83.59
Environmental								
Emissions reduction initiatives	No							
Climate change policy	No	No	No	No	Yes	Yes	Yes	Yes
Climate change opportunities discussed	No							
Risks of climate change discussed	No							
GHG scope 1	_	_	3	4	9	35	9	34
GHG scope 2 location-based	_	_	91	92	98	94	96	209
GHG Scope 3	_	_	_	_	_	_	_	_
Carbon per unit of production	_	_	_	_	_	_	_	_
Biodiversity policy	No							
Energy efficiency policy	No	No	Yes	Yes	Yes	Yes	Yes	Yes
Total energy consumption	_	_	143	145	152	147	194	497
Renewable energy use	_	_	_	_	_	_	_	5
Electricity used	_	_	143	145	152	147	192	417
Fuel used - natural gas	_	_	_	_	_	_	_	_

Sources: Bloomberg; FSSIA's compilation

Exhibit 5: ESG score by Bloomberg (cont.)

Y ending Dec 31	FY 2015	FY 2016	FY 2017	FY 2018	FY 2019	FY 2020	FY 2021	FY 20:
Fuel used - crude oil/diesel	No	No	No	No	No	No	No	1
Waste reduction policy	No	No	No	Yes	Yes	Yes	Yes	Y
Hazardous waste	_	_	1	2	2	2	3	
Total waste	_	_	6	7	7	5	9	
Waste recycled	_	_	0	1	1	0	1	
Waste sent to landfills	_	_	_	_	_	_	3	
Environmental supply chain management	No	No	No	No	Yes	Yes	Yes	Y
Water policy	No	No	No	Yes	Yes	Yes	Yes	Y
Water consumption	_	_	354	358	388	332	472	7
ocial								
Human rights policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Υ
Policy against child labor	No	No	No	No	No	Yes	Yes	Υ
Quality assurance and recall policy	No	No	No	No	Yes	Yes	Yes	Υ
Consumer data protection policy	No	No	Yes	Yes	Yes	Yes	Yes	Υ
Equal opportunity policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Υ
Gender pay gap breakout	No	No	No	No	No	No	No	
Pct women in workforce	_	_	82	82	82	82	83	
Pct disabled in workforce	_	_	_	_	_	_	_	
Business ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Y
Anti-bribery ethics policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	Y
Health and safety policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	١
Lost time incident rate - employees	_	_	0	0	0	0	0	
Total recordable incident rate - employees	_	_	2	2	2	1	1	
Training policy	Yes	Yes	Yes	Yes	Yes	Yes	Yes	•
Fair remuneration policy	No	No	No	No	No	No	No	
Number of employees – CSR	33,456	36,989	37,505	38,803	40,298	36,254	36,344	40,
Employee turnover pct	· —	· —	18	19	19	17	16	,
Total hours spent by firm - employee training	568,960	588,890	795,330	547,592	784,625	476,816	437,209	1,417,
Social supply chain management	No	No	No	No	Yes	Yes	Yes	,
overnance								
oard size	15	14	13	14	14	16	18	
o. of independent directors (ID)	7	6	6	6	6	7	7	
No. of women on board	2	1	1	1	1	2	2	
No. of non-executive directors on board	9	7	6	8	9	9	9	
Company conducts board evaluations	Yes	Yes	Yes	Yes	Yes	Yes	Yes	,
No. of board meetings for the year	13	13	14	12	13	12	12	
Board meeting attendance pct	95	94	98	97	98	98	97	
Board duration (years)	3	3	3	3	3	3	3	
irector share ownership guidelines	No	No	No	No	No	No	No	
ge of the youngest director	45	42	43	44	45	46	47	
ge of the youngest director	83	84	45 85	86	87	88	89	
o. of executives / company managers	4	5	5	5	6	7	5	
No. of female executives	1	1	1	2	1	2	2	
Executive share ownership guidelines	No	No	No	No	No	No	No	
ize of audit committee	3	3	3	3	3	3	3	
No. of ID on audit committee	3	3	3	3		3	3	
Audit committee meetings	10	9	10	3 7	3 10	6	6	
•								
Audit meeting attendance %	100	100	100	100	97	100	100	
ize of compensation committee	4	4	4	4	4	3	3	
No. of ID on compensation committee	3	3	3	2	2	2	2	
No. of compensation committee meetings	3	1	4	4	3	4	4	
Compensation meeting attendance %	100	100	100	100	100	100	100	
ize of nomination committee	4	4	4	4	4	3	3	
No. of nomination committee meetings	3	1	4	4	3	4	4	
Nomination meeting attendance %	100	100	100	100	100	100	100	
ustainability governance								

Sources: Bloomberg; FSSIA's compilation

# **Disclaimer for ESG scoring**

ESG score	Methodolog	<b>у</b>			Rating						
The Dow Jones Sustainability Indices ( <u>DJSI</u> ) By S&P Global	process bas from the ann	ed on the comp nual S&P Globa	ransparent, rules-based panies' Total Sustainabili al Corporate Sustainabilit inies within each industry	ity Scores resulting ty Assessment (CSA).	Sustainability A ESG Score of I	Assessment (C ess than 45% ny are disqual	he annual S&P ( SA) for DJSI. Co of the S&P Glob ified. The constit iverse.	mpanies with al ESG Score	an S&P Globa of the highest		
Sustainability nvestment List (THSI) by The Stock Exchange of Thailand (SET)	managing be Candidates 1) no irregul float of >150 up capital. S 70%; 2) inde wrongdoing	usiness with tra must pass the par trading of the shareholders, come key disque ependent direct related to CG,	ity in Environmental and unsparency in Governand preemptive criteria, with e board members and ex and combined holding alifying criteria include: 1 ors and free float violatic social & environmental in arnings in red for > 3 year	ce, updated annually. two crucial conditions: tecutives; and 2) free nust be >15% of paid- 1) CG score of below on; 3) executives' mpacts; 4) equity in	minimum of 50 during the asse nature of the research services and the services services services and the services services and the services se	% for each indessment year. elevant industr selevant industr <u>x</u> is extended THB5b (~US up capital for a tet capitalisation	sion, verified dat dicator, unless the The scoring will I y and materiality from the THSI oc D150b); 2) free fl at least 9 out of 1 on-weighted inde mber of stocks.	e company is be fairly weigh ompanies who oat >20%; and 2 months. The	a part of DJSI nted against the se 1) market d 3) liquidity e SETTHSI		
CG Score by Thai nstitute of Directors Association Thai IOD)	annually by Thailand (SI	the Thai IOD, v	in sustainable developn vith support from the Sto s are from the perspectiv	ck Exchange of	Good (80-89), and not rated for equitable treater	3 for Good (70 or scores belo ment of sharel 25%); 4) disclo	ories: 5 for Excel 0-79), 2 for Fair (6 w 50. Weightings nolders (weight 2 osure & transpare	60-69), 1 for P s include: 1) th 5% combined	lass (60-69), ne rights; 2) an ); 3) the role o		
AGM level By Thai nvestors Association (TIA) with support from the SEC	treatment ar transparent out of five th criteria cove date (45%), circulation of s exercised. The and verifiability	e incorporated and sufficiently e CG compone r AGM procedu and after the matter information assesses and 3) opennes and 3) opennes	hich shareholders' rights into business operations disclosed. All form impo ents to be evaluated annures before the meeting (10%). (The first as on for voting; and 2) facilitations to the ease of attending mess for Q&A. The third involves, resolutions and voting res	a and information is intant elements of two ually. The assessment (45%), at the meeting assesses 1) advance ing how voting rights can be eetings; 2) transparency is the meeting minutes that			o four categories: · (80-89), and not				
Fhai CAC By Thai Private Sector Collective Action Against Corruption CAC)	establishme policies. The (Companies of Declaration of Certification, in managers and	nt of key control c Certification is eciding to become Intent to kick off a ncluding risk asse	thecklist include corruptions, and the monitoring and so good for three years.  The a CAC certified member stan 18-month deadline to subsement, in place of policy and blishment of whistleblowing stakeholders.)	nd developing of  art by submitting a mit the CAC Checklist for ad control, training of	The document will be reviewed by a committee of nine professionals. A passed Checklist will move for granting certification by the CAC Council approvals whose members are twelve highly respected individuals in professionalism and ethical achievements.						
Morningstar Sustainalytics	based on an risk is unma	assessment of naged. Sources	k rating provides an ove f how much of a compan to be reviewed include corpo er media, NGO reports/webs	ny's exposure to ESG prate publications and			score is the sum higher ESG risk		ed risk. The		
		ompany feedback uality & peer revie	, ESG controversies, issuer t ews.	feedback on draft ESG	<b>NEGL</b> 0-10	<b>Low</b> 10-20	Medium 20-30	<b>High</b> 30-40	Severe 40+		
ESG Book	positioned to the principle helps explai over-weighti	o outperform ov of financial ma n future risk-ad	ustainable companies the ver the long term. The me teriality including informa justed performance. Mat h higher materiality and in ly basis.	ethodology considers ation that significantly eriality is applied by	scores using m	ateriality-base	ated as a weight ad weights. The s ndicating better p	core is scaled			
<u>MSCI</u>			neasure a company's ma d laggards according to t						nethodology to		
	AAA	8.571-10.000	l d	1		·:64 F00	-1 1				
	AA	7.143-8.570	Leader:	leading its industry in m	anaging the most s	igrillicant ESG fi	sks and opportunitie	55			
	Α	5.714-7.142									
	ВВВ	4.286-5.713	Average:	a mixed or unexceptional industry peers	ai track record of m	anaging the mos	st significant ESG ris	sks and opportu	nities relative to		
	ВВ	2.857-4.285		, .							
	В	1.429-2.856	Laggard:	lagging its industry base	ed on its high expos	ure and failure t	o manage significar	nt ESG risks			
	CCC	0.000-1.428	33*****	55 5 2001, 2000	g., s.,poc		gg3di				
Moody's ESG olutions	believes tha	t a company int	ree to which companies t tegrating ESG factors int r shareholders over the r	o its business model and							
Refinitiv ESG ating	based on pu	ıblicly available	and objectively measure and auditable data. The a publicly. (Score ratings a	score ranges from 0 to	100 on relative E	SG performar	nce and insufficie	nt degree of t			
S&P Global			e is a relative score mea n the same industry clas				of ESG risks, op	portunities, ar	impacts		
Bloomberg	ESG Score		score is based on Bloom	ating the company's aggi nberg's view of ESG fina the weights are determin	ncial materiality.	The score is	a weighted gener	ralized mean	(power mean)		
	ESG Disclos		Disclosure of a compan								

Rating regarding the sustainable development of Thai listed companies, both on the SET and MAI, are publicly available on the website of the Securities and Exchange Commission of Thailand (SEC). Currently, ratings available are 1) "CG Score"; 2) "AGM Level"; 3) "Thai CAC"; and 4) THSI. The ratings are updated on an annual basis. FSSIA does not confirm nor certify the accuracy of such ratings.

Source: FSSIA's compilation

#### **GENERAL DISCLAIMER**

### ANALYST(S) CERTIFICATION

### Teerapol Udomvej, CFA FSS International Investment Advisory Securities Co., Ltd

The individual(s) identified above certify(ies) that (i) all views expressed in this report accurately reflect the personal view of the analyst(s) with regard to any and all of the subject securities, companies or issuers mentioned in this report; and (ii) no part of the compensation of the analyst(s) was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed herein.

This report has been prepared by FSS International Investment Advisory Securities Company Limited (FSSIA). The information herein has been obtained from sources believed to be reliable and accurate; however FSSIA makes no representation as to the accuracy and completeness of such information. Information and opinions expressed herein are subject to change without notice. FSSIA has no intention to solicit investors to buy or sell any security in this report. In addition, FSSIA does not guarantee returns nor price of the securities described in the report nor accept any liability for any loss or damage of any kind arising out of the use of such information or opinions in this report. Investors should study this report carefully in making investment decisions. All rights are reserved.

This report may not be reproduced, distributed or published by any person in any manner for any purpose without permission of FSSIA. Investment in securities has risks. Investors are advised to consider carefully before making investment decisions.

#### History of change in investment rating and/or target price



Date	Rating	Target price	Date	Rating	Target price	Date	Rating	Target price
16-Nov-2021	BUY	29.00	06-Oct-2022	BUY	33.00	18-Jan-2024	BUY	35.00
19-Apr-2022	BUY	31.00	08-Jan-2023	BUY	34.50	10-Oct-2024	BUY	36.50

Teerapol Udomvej, CFA started covering this stock from 30-Jul-2020

Price and TP are in local currency

Source: FSSIA estimates

Company	Ticker	Price	Rating	Valuation & Risks
Bangkok Dusit Medical Services	BDMS TB	THB 25.75	BUY	Downside risks to our DCF-based target price include 1) a slowdown in international patients due to economic concerns, political protests or floods; 2) regulatory risks from drug prices and medical bill controls; and 3) higher-than-expected capex and opex for CoE projects.

Source: FSSIA estimates

#### **Additional Disclosures**

Target price history, stock price charts, valuation and risk details, and equity rating histories applicable to each company rated in this report is available in our most recently published reports. You can contact the analyst named on the front of this note or your representative at Finansia Syrus Securities Public Company Limited.

All share prices are as at market close on 12-Nov-2024 unless otherwise stated.

# RECOMMENDATION STRUCTURE

### Stock ratings

Stock ratings are based on absolute upside or downside, which we define as (target price\* - current price) / current price.

BUY (B). The upside is 10% or more.

HOLD (H). The upside or downside is less than 10%.

REDUCE (R). The downside is 10% or more.

Unless otherwise specified, these recommendations are set with a 12-month horizon. Thus, it is possible that future price volatility may cause a temporary mismatch between upside/downside for a stock based on market price and the formal recommendation.

\* In most cases, the target price will equal the analyst's assessment of the current fair value of the stock. However, if the analyst doesn't think the market will reassess the stock over the specified time horizon due to a lack of events or catalysts, then the target price may differ from fair value. In most cases, therefore, our recommendation is an assessment of the mismatch between current market price and our assessment of current fair value.

### **Industry Recommendations**

Overweight. The analyst expects the fundamental conditions of the sector to be positive over the next 12 months.

Neutral. The analyst expects the fundamental conditions of the sector to be maintained over the next 12 months.

Underweight. The analyst expects the fundamental conditions of the sector to be negative over the next 12 months.

#### **Country (Strategy) Recommendations**

**Overweight (O).** Over the next 12 months, the analyst expects the market to score positively on two or more of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Neutral (N).** Over the next 12 months, the analyst expects the market to score positively on one of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.

**Underweight (U).** Over the next 12 months, the analyst does not expect the market to score positively on any of the criteria used to determine market recommendations: index returns relative to the regional benchmark, index sharpe ratio relative to the regional benchmark and index returns relative to the market cost of equity.